How Science Corporation’s PRIMA system restores prosthetic central vision in advanced AMD
Science Corporation launches CE-marked PRIMA in Europe, but reimbursement, specialist training and real-world outcomes will determine access.
Medical Devices & Diagnostics
Pharma & Biotech
Can Lineage turn early retinal repair signals into a credible late-stage OpRegen pathway?
Discover why Lineage Cell Therapeutics’ OpRegen and OPC1 programmes now face critical delivery, trial design and manufacturing tests.
Pharma & Biotech
Can L’Oréal-backed funding help OliX Pharmaceuticals turn siRNA science into a broader biotech platform?
Find out how OliX Pharmaceuticals’ KRW 110 billion raise could reshape RNAi therapeutics, beauty biotech, and siRNA platform strategy.
Pharma & Biotech
Can Bausch + Lomb’s PreserVision AREDS3 shift the AMD supplement market beyond AREDS2 alone?
Bausch + Lomb’s PreserVision AREDS3 adds B vitamins to the AMD nutrition debate. Read what this could change for eye health and market strategy.
Pharma & Biotech
Samsung Bioepis takes over BYOOVIZ commercialization in Europe after Biogen exit
Samsung Bioepis has officially begun direct commercialization of BYOOVIZ, a biosimilar to Lucentis (ranibizumab), across Europe following the complete transfer of rights from Biogen. The move makes BYOOVIZ the fourth biosimilar now independently marketed by Samsung Bioepis in the region, joining EPYSQLI (eculizumab), OBODENCE (denosumab), and XBRYK (denosumab). The company also confirmed that a pre-filled